Trial Profile
A Randomized, Double-Blind Placebo-Controlled Exploration of a Topical Menadione-Containing Lotion to the Face for Prevention and Palliation of Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Discomfort and Psychological Distress
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Menadione (Primary)
- Indications Exanthema
- Focus Therapeutic Use
- 27 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Mar 2025.
- 06 Oct 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 29 Sep 2020 Planned End Date changed from 1 Dec 2020 to 31 Dec 2021.